Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Down 23.0% in December

Delcath Systems, Inc. (NASDAQ:DCTH) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 1,040,000 shares, a decrease of 23.0% from the December 15th total of 1,350,000 shares. Based on an average daily trading volume, of 386,900 shares, the days-to-cover ratio is presently 2.7 days.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Delcath Systems in a research note on Tuesday. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group restated a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. Craig Hallum increased their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday. Finally, StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.25.

Delcath Systems Stock Up 4.7 %

Delcath Systems stock traded up $0.64 during midday trading on Friday, hitting $14.31. The company’s stock had a trading volume of 573,890 shares, compared to its average volume of 303,529. Delcath Systems has a 12 month low of $3.70 and a 12 month high of $14.47. The company has a market capitalization of $457.49 million, a PE ratio of -10.60 and a beta of 0.87. The stock’s 50-day moving average price is $11.48 and its 200-day moving average price is $9.92.

Institutional Trading of Delcath Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. acquired a new position in shares of Delcath Systems in the 3rd quarter valued at $808,000. Virtu Financial LLC purchased a new stake in Delcath Systems during the third quarter valued at about $289,000. Barclays PLC acquired a new position in shares of Delcath Systems in the third quarter worth about $104,000. Geode Capital Management LLC increased its position in shares of Delcath Systems by 3.0% in the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock worth $2,275,000 after acquiring an additional 7,298 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Delcath Systems in the third quarter worth approximately $110,000. 61.12% of the stock is owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.